Roivant · 12 hours ago
Accounts Payable Specialist
Roivant is a biopharmaceutical company dedicated to improving patient lives by accelerating the development and commercialization of important medicines. The Accounts Payable Specialist will be responsible for maintaining all phases of the accounts payable process and collaborating with various teams to ensure timely and accurate execution.
BiopharmaBiotechnologyHealth CarePharmaceuticalProduct Research
Responsibilities
Read and understand financial terms of contracts for the establishment and maintenance of invoices
Read and understand invoices for proper matching and coding against purchase orders and Non-PO invoices
Ensure proper approvals are obtained for invoices
Upload appropriate supporting documentation into the accounting system
Maintain accounting mailbox and the Invoice mailbox in Coupa
Prepare and submit Payment runs in NetSuite
Qualification
Required
2+ years of relevant experience
Pharmaceutical experience with clinical trials a plus
Knowledge of Excel and major ERP systems; NetSuite a plus, Coupa a Plus
Process-oriented
Attention to detail
Effective at internal control over business processes
Effective at cross-departmental work
Highly organized and strong communicator
Benefits
Discretionary bonuses
Equity
Company-sponsored benefit programs
Company
Roivant
Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients.
H1B Sponsorship
Roivant has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (2)
2024 (1)
2023 (8)
2022 (10)
2021 (8)
2020 (4)
Funding
Current Stage
Public CompanyTotal Funding
$2.47BKey Investors
SoftBank Vision FundViking Global InvestorsQVT Financial
2023-02-02Post Ipo Equity· $230M
2022-11-08Post Ipo Equity· $150M
2021-10-01Post Ipo Equity· $200M
Recent News
MarketScreener
2025-12-19
MarketScreener
2025-12-18
2025-12-12
Company data provided by crunchbase